Introduction
Experimental objectives, methods and results
General conclusion
Salmonella infections in humans are often linked with the consumption of contaminated pork [1] [2] . Vaccination has been proposed to control Salmonella infections in pigs [1] [3] [4] and has already proven to be efficient in laying hens, reducing faecal shedding and internal egg contamination [5] [6] . The use of vaccines in pigs is currently limited due to interference with European Salmonella serosurveillance programmes based on the detection of antibodies against the lipopolysaccharides (LPS) of Salmonella [7] . It was therefore the aim of this study to develop a DIVA-vaccine marker (Differentiation of Infected and Vaccinated Animals), without affecting immunization capacity of this strain, that would avoid interference with current LPS-ELISA based serosurveillance programmes.
Vaccination of mice with ∆rfbA, ∆rfaL and ∆rfaJ but not ∆rfaI, ∆rfaG and ∆rfaF induces protection in mice against a Salmonella Typhimurium infection Pigs, immunized with the rfaJ or rfaL mutant , can be serologically differentiated from Salmonella infected animals In conclusion, we provide proof of concept that deletions in the rfaJ or the rfaL gene in Salmonella Typhimurium strain 112910a allows differentiation of infected and vaccinated pigs in an LPS based ELISA without reducing the strain's protective capacities in mice. Further research in pigs is underway. We examined if it was possible to discriminate between the serological response induced after vaccination of pigs with adjuvanted bacterins of either Salmonella Typhimurium strain 112910a or one of its isogenic LPS mutant strains (∆rfaL ∆rfaJ). Secondly we compared this with the serological response of pigs after infection with Salmonella Typhimurium strain 112910a. Therefore, 14 piglets were randomly allocated to three vaccination groups (n = 12) and one sham-immunized control group (n = 2). The animals were intramuscularly immunized with one of the formalin-inactivated Salmonella strains (either: Salmonella Typhimurium strain 112910a, ∆rfaJ or ∆rfaL) in Freund's incomplete adjuvant. To obtain sera from Salmonella Typhimurium infected piglets, one experimental group (n = 3) was orally inoculated with approximately 2 ͯ 10 7 CFU of Salmonella Typhimurium strain 112910a Nal20 .
Conclusion:
Anti-Salmonella-antibody titers were detected in the serum of all immunized and infected animals, when using an in-house whole cell ELISA. No significant seroconversion was seen (P > 0.05) in animals immunized with inactivated ∆rfaJ or ∆rfaL strains and in sham-immuized control animals (non immunized and non infected animals), when using the commercial IDEXX ELISA. Conversely, marked seroconversion occurred in pigs immunized with the inactivated Salmonella Typhimurium strain 112910a. Results illustrate a clear differentiation between sera from piglets immunized with the ∆rfaJ strain or ∆rfaL strain and sera of pigs infected with their isogenic wild type strain. Anti-Salmonella-antibody titers were detected in the serum of all immunized and infected animals, when using an in-house whole cell ELISA. Results are shown in figure 2. We tested whether mutations in the LPS of Salmonella Typhimurium strain 112910a affect its protective capacity against a subsequent challenge with a highly virulent strain.
For that purpose, seven groups of ten mice were immunized via the orogastric route with 10 7 CFU of one of the LPS mutant strains (either: ∆rfbA, ∆rfaL, ∆rfaJ, ∆rfaI, ∆rfaG or ∆rfaF) or with the wild type Salmonella Typhimurium strain 112910a. Four weeks after immunization, all mice were challenged with 10 8 CFU of the virulent Salmonella Typhimurium strain NCTC12023 Nal20 by the orogastric route. Mice were euthanized nine days post challenge.
Oral immunization of mice with Salmonella Typhimurium strain 112910a, ∆rfbA, ∆rfaL or ∆rfaJ induced a significant (P < 0.05) protection against subsequent challenge with NCTC12023 Nal20 in both spleen and liver compared to non immunized control animals. Results are shown in figure 1. 
